KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation

Cochrane Database of Systematic Reviews 2026 Open access

Read full text
Authors: Anneloes L. Noordhof, Oke Dimas Asmara, Kim de Jong, Rolof G.P. Gijtenbeek, Ymkje MA Huitema, Femke H. M. van Vollenhoven, Ben J.W. Venmans, Lizza E.L. Hendriks, Wouter Heero van Geffen
DOI: 10.1002/14651858.cd016054
Cited by: 0
References: 37

Abstract

OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of G12C-inhibitors compared to chemotherapy in second line and beyond in adults with advanced/metastatic non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma (KRAS) G12C mutation.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies

Publication details

Journal / source
Cochrane Database of Systematic Reviews
Volume
2026
Issue
2
Pages
CD016054–CD016054
Publication date
17 February 2026
Language
EN